DECATUR
GenericsDECATUR is a generic drug manufacturer focused on Oncology.
DECATUR's Key Drugs
DECATUR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
DECATUR's Recent FDA Approvals
New NDA/BLA approvals for DECATUR over the last two years — novel drugs only, excluding generics and label supplements.
DECATUR's Therapeutic Areas
DECATUR's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DECATUR's Top Competitors
DECATUR's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DECATUR Pipeline Snapshot
Active clinical trials for DECATUR across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-10-21
- Latest
- 2018-03-26
- Applications
- 2